Search: onr:"swepub:oai:DiVA.org:uu-490863" >
Central nervous sys...
Central nervous system hemangioblastomas in von Hippel-Lindau disease : Total growth rate and risk of developing new lesions not associated with circulating VEGF levels
-
- Sundblom, Jimmy, 1981- (author)
- Uppsala universitet,Neurokirurgi
-
- Persson Skare, Tor (author)
- Uppsala universitet,Institutionen för immunologi, genetik och patologi
-
- Holm, Olivia (author)
- Uppsala universitet,Neurokirurgi
-
show more...
-
- Welin, Staffan (author)
- Uppsala universitet,Onkologisk endokrinologi
-
- Braun, Madelene (author)
- Uppsala universitet,Neurologi
-
- Nilsson, Pelle (author)
- Uppsala universitet,Neurokirurgi
-
- Enblad, Per (author)
- Uppsala universitet,Neurokirurgi
-
- Ohlin Sjöström, Elisabet (author)
- Uppsala universitet,Institutionen för immunologi, genetik och patologi
-
- Smits, Anja (author)
- Uppsala universitet,Neurologi
-
show less...
-
(creator_code:org_t)
- 2022-11-28
- 2022
- English.
-
In: PLOS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 17:11
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- BACKGROUND: Hemangioblastomas of the central nervous system are a prominent feature of von Hippel-Lindau-disease (vHL). Hemangioblastomas are known to secrete vascular endothelial growth factor (VEGF), suggesting a potential role of VEGF as a biomarker for tumor growth.METHODS: Plasma VEGF samples from 24 patients with von Hippel-Lindau disease were analyzed by solid-phase proximity ligation assay (PLA). Levels were monitored over time together with numeric and volumetric CNS tumor burden, and compared to plasma VEGF levels in healthy controls.RESULTS: The mean yearly progression in tumor volume was 65.5%. Yearly risk of developing one or several new CNS tumor(s) was 50%. No significant correlation between tumor burden and levels of VEGF was seen. VEGF levels in patients (31.55-92.04; mean 55.83, median 56.41) as measured by immunodetection in a solid-phase PLA did not differ significantly from controls (37.38-104.56; mean 58.89, median 54.12) (p = 0,266).CONCLUSION: The increase in total CNS tumor volume in vHL occurred in a saltatory manner. The risk of developing a new lesion was 50% per year. We found no evidence for VEGF secretion from CNS hemangioblastomas in vHL in circulating blood. Other potential biomarkers should be explored to assess progression of tumor burden in vHL.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
-
PLOS ONE
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Sundblom, Jimmy, ...
-
Persson Skare, T ...
-
Holm, Olivia
-
Welin, Staffan
-
Braun, Madelene
-
Nilsson, Pelle
-
show more...
-
Enblad, Per
-
Ohlin Sjöström, ...
-
Smits, Anja
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Neurology
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
PLOS ONE
- By the university
-
Uppsala University